SNAMPXIN Substrate FRET Signal for Neurotoxin Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting Clostridium neurotoxins, particularly botulinum neurotoxins, are inadequate due to lack of rapid and sensitive diagnostics, inability to differentiate active from inactive toxins, and require extensive resources and animal testing, posing challenges for public health and biodefense.
Innovation Solution
Development of a recombinant substrate called SNAMPXIN, flanked by fluorescent proteins, which undergoes FRET signal change upon cleavage by biologically active Clostridium neurotoxin, enabling serotype-specific detection using a high-throughput automated system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If traditional detection methods are used, then detection capability is maintained, but detection speed and sensitivity are insufficient
Solution Approach 1:
The patent replaces traditional mechanical/biological detection systems (animal testing, manual assays) with an automated fluorescence-based detection system. The SNAMPXIN substrate combined with fluorescent proteins and FRET signaling enables rapid, sensitive, and automated detection of botulinum neurotoxin, eliminating the need for animal testing and manual interpretation while improving both speed and reliability.
2Measurement precision
If animal testing is used for detection, then detection accuracy is achieved, but resource consumption and ethical concerns increase
Solution Approach 1:
The patent creates a molecular copy of the detection system using fluorescent proteins and FRET-based substrates instead of actual animal models. The SNAMPXIN substrate with embedded fluorescent tags provides a surrogate system that mirrors the biological detection function without requiring animal testing, thereby maintaining accuracy while eliminating resource consumption and ethical concerns associated with animal experimentation.
3Measurement precision
If serotype-specific detection is implemented, then identification accuracy is improved, but detection complexity increases
Solution Approach 1:
The patent develops a universal detection substrate SNAMPXIN that can detect multiple botulinum neurotoxin serotypes through a single assay system. The substrate is designed with multiple cleavage sites corresponding to different serotypes, allowing one reagent to perform multiple detection functions. This multi-functionality enables serotype-specific identification through fluorescence analysis without requiring separate detection systems for each serotype, thereby improving accuracy while managing complexity.
4Loss of time
If rapid detection is implemented, then response time is reduced, but detection sensitivity may be compromised
Solution Approach 1:
The patent optimizes the detection parameters including fluorescence emission wavelengths, FRET ratios, and substrate concentrations to achieve rapid detection without sacrificing sensitivity. The use of fluorescent proteins with specific emission characteristics and FRET-based signaling allows for quick signal acquisition and analysis while maintaining high sensitivity for low levels of neurotoxin. Parameter optimization enables simultaneous achievement of speed and precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for rapid, sensitive, and serotype-specific detection of active Clostridium neurotoxins, reducing the need for animal testing and resources, while providing statistically reproducible results and safer laboratory protocols.
Implementation Method 1
The cleavage of the substrate by biologically active Clostridium neurotoxin will result in the Foster resonance energy transfer (FRET) signal change for the detection
Data Source
AI summary
The present invention provides a method for detecting and assaying Clostridium neurotoxins and identification of serotypes of botulinum neurotoxins in various food matrices and clinical samples. This method is also used for detection of BoNT inside the neuronal and epithelial cells. The method comprises detecting and assaying the presence of a Clostridium neurotoxin in a sample by: exposing the sample containing a Clostridium neurotoxin to a sample comprising a novel SNAMPXIN/SNAMP universal recombinant substrate fusion protein capable of producing a detectable FRET, following cleavage; detecting and assaying the presence of the Clostridium neurotoxin by measuring a change in the energy transfer or the luminescence signal; and detecting and assaying an electrophoretic mobility pattern of one or more cleaved protein bands or a degraded protein, using a high throughput automated system to identify the different serotypes of the Clostridium neurotoxin. SNAMPXIN/SNAMP is formed from parts of BoNT substrates SNAP-25 and VAMP.